Science
Partnerships
About
News & Media
Careers
Twitter
LinkedIn
hello@kernalbio.com
Synthetic biologists.
Immunologists.
Data scientists.
Together, we’re making designer mRNA drugs to
cure serious illnesses
.
Drugs that
leverage
our
immune system
rather than work against it. Drugs that are more
accessible
to more people. Drugs that
put humans first
.
Team
Yusuf Erkul
MD
Chief Executive Officer & Cofounder
Physician entrepreneur who developed an FDA-approved cancer drug at Merck & Co
Burak Yilmaz
MS
President & Cofounder
Serial entrepreneur and synthetic biologist who founded his first biotech company at age 22
Maria
Grunwald
PhD, MBA
Chief Business Officer
Transactional business development executive with 18 years of experience in biopharma
Manfred Kraus
PhD
VP, Head of R&D Therapeutics
Cafer Ozdemir
PhD
Director of Convergence Science & Cofounder
Rudy Christmas
In Vivo Pharmacologist
Jieni Xu
PhD, PMP
Senior Scientist
Maxwell Alexander
MS
Computational Biology, Data Science
Tom Addison
Senior Associate Scientist, Synthetic Biology
Sadik Yildiz
PhD
Data Scientist
Drishti
Parwanda
MS
Intern, Immunology
Shaunak Kerkar
Intern, Formulation
Advisory
Board
Arthur Krieg
MD
Clinical Advisor, Nucleic Acid Therapeutics
Founder / CEO / CSO of 4 successful nucleic acid companies
Edward Benz Jr
MD
Clinical Advisor, Medical Oncology
President & CEO Emeritus of Dana Farber Cancer Institute, Harvard Medical School
Peter
Blume-Jensen
MD, PhD
Clinical Advisor, Cancer Drug Development
CEO of Acrivon Therapeutics and former Head of Oncology at of Merck
Nikolai Slavov
PhD
Scientfic Advisor, mRNA Translation
Associate Professor, Northeastern University
Dean
Felsher
MD, PhD
Clinical Advisor, Translational Oncology
Director of Stanford Medicine Translational Research & Applied Medicine at Stanford Medical School
Dan Peer
PhD
Scientific Advisor
Vice President for R&D, Tel Aviv University
This
could
be you.
Careers